🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT07437547
Recruiting Phase 2

BPC 157 for Acute Hamstring Muscle Strain Repair

NCT07437547 · tracked via the Priya Life Science China tracker
Sponsor
Hudson Biotech
Phase
Phase 2
Started
2026-02-02
Last updated
2026-02-27

Condition(s) studied

Hamstring Muscle StrainSkeletal Muscle Injury

Investigational drug(s) / intervention(s)

Pentadecapeptide BPC 157Placebo

Pentadecapeptide BPC 157: subcutaneous injection (administered by trained study staff). Schedule: once daily for 14 days.

Placebo: subcutaneous injection (administered by trained study staff). Schedule: once daily for 14 days.

Study summary

This randomized, double-blind, placebo-controlled Phase 2 study evaluates whether pentadecapeptide BPC 157 (BPC-157), an investigational peptide, can speed structural healing and functional recovery after an acute grade II hamstring muscle strain. Participants will receive BPC 157 or placebo for 14 days in addition to a standardized rehabilitation program. The co-primary endpoints are time to return to unrestricted sport and change in MRI-assessed injury volume at Day 14.

Eligibility

Sex
ALL
Min age
18 Years
Max age
45 Years
Healthy volunteers
No
Inclusion Criteria: * Age 18 to 45 years. * Acute posterior thigh pain consistent with hamstring strain with onset within 72 hours prior to screening. * MRI-confirmed grade II hamstring strain of the biceps femoris, semitendinosus, or semimembranosus, with measurable lesion. * Pre-injury physical activity \>= 3 sessions/week or participation in organized recreational sport. * Willingness to follow the standardized rehabilitation protocol and attend all study visits. * For participants of childbearing potential: negative pregnancy test at baseline and agreement to use effective contraception during dosing and for 30 days after last dose. Exclusion Criteria: * Grade III hamstring tear, tendon avulsion, or injury requiring surgical management. * Concomitant lower extremity injury that would interfere with rehabilitation or outcome assessment. * Prior hamstring strain on the index limb within the past 6 months. * Use of systemic corticosteroids, anabolic agents, platelet-rich plasma, stem-cell products, or investigational peptides/growth factors within 30 days prior to screening. * Known bleeding disorder or current therapeutic anticoagulation. * Significant uncontrolled medical illness (e.g., severe cardiovascular, hepatic, or renal disease) that increases study risk. * Known allergy or hypersensitivity to components of the investigational product or placebo. * Pregnant or breastfeeding. * Current participation in another interventional clinical study or participation within 30 days prior to screening. * Currently subject to a formal anti-doping testing program (e.g., WADA/USADA-aligned) where use of an investigational peptide could create a regulatory conflict, unless explicitly approved by the relevant authority

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Peking University Shenzhen Hospital Shenzhen Guangdong Recruiting

More Hudson Biotech trials in China

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07437547 on ClinicalTrials.gov ↗ ← All trials in China